Loading candles…
Sai Life Sciences Ltd was incorporated in 1999 and operates in the pharmaceutical and biotechnology industries. The company provides contract research, development, and manufacturing services, focusing on supporting drug discovery, development, and commercial manufacturing for New Chemical Entities. Sai Life Sciences conducts its operations through innovative research laboratories located in global hubs and cost-efficient, large-scale manufacturing facilities in India. It maintains relationships with 18 of the top 25 global pharmaceutical companies and serves over 300 active customers worldwide, including markets in the US, UK, Europe, Japan, and India. The company's business segments include contract research, development, and manufacturing services for its clients in the pharma and biotech sectors.
| Type | Details | Date |
|---|---|---|
| Audited Results - Q4 & FY26 | To consider and approve the Audited Financial Results (Standalone & Consolidated) for the fourth quarter and year ended March 31, 2026 | 14 May 2026 |
| Unaudited Results - Q3-FY25 | To consider and approve the Un-audited Financial Results for the third quarter and nine months ended December 31, 2025. | 5 Feb 2026 |
| Unaudited Results - FY25 | To consider and approve the Un-audited financial results (Standalone and Consolidated) for the period ended September 30, 2025 | 6 Nov 2025 |
| Unaudited Results - Q1-FY25 | To consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended Jun 30, 2025 | 7 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and other business matters | 13 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.